Impact of U.S. Most-Favored-Nation Pricing Model on Global Product Launches & Pricing In May 2025, President Donald Trump signed the executive order introducing a ‘Most-Favored-Nation’ pricing model, aimed at equalizing U.S. drug prices with similar [...]
Sample Regulatory Assessment for Treatment Access Program The WEP Regulatory team has created this resource to highlight the heterogenous regulatory landscape across treatment access programs including Expanded Access Programs (EAPs), Compassionate Use Programs, and Named [...]
Sponsor Considerations for Post-Trial Access If you are coming to the end of your clinical trial, you may have started thinking about if and how to provide post-trial access for patients.To help Sponsors, WEP has [...]
Harnessing Real-World Data for Market Access Success Download our free resource exploring the value of Real World Data (RWD). Collecting RWD can help inform your market access strategy and prepare you for successful product launch. [...]
Step-by-step EAP Management process The infographic outlines the processes involved in running an end-to-end Expanded Access Program (EAP). Companies need to understand all elements involved, to ensure efficient and consistent medicine supply to patients throughout [...]
NAVIGATING ASSET TRANSITIONS THAT INCLUDE EAPs A common challenge for many companies during asset movements is the transition of Expanded Access Programs (EAPs). EAPs are often overlooked in the initial agreements and transition plans, leading [...]
BUILDING STAKEHOLDER ENGAGEMENT THROUGH EAPs Download our guide on leveraging Early Access Programs to engage healthcare professionals, payers, and empower eligible patients with early access to innovative therapies. Gain valuable insights, contribute to real-world evidence, [...]
International Recognition Procedure From January 2024, the MHRA is adopting the International Recognition Procedure, reflecting a strategic pivot towards an independent and collaborative regulatory framework for swift and secure drug authorizations in the UK. Our [...]
Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) The new VPAG scheme is due to come in effect in January 2024 lasting for 5 years. The scheme, which has been agreed between the [...]
Managing patient requests for Your investigational medicines Expanded Access Programs (EAPs) allow companies to provide their investigational medicines to patients outside of the clinical trial setting, to fulfil unmet clinical needs.WEP has put together a [...]
